BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

Isolating tumor antigen-specific T cellsScripps Research Institute scientists have described in Cell a method, coined FucoID, to detect and separate T cells that react to tumor-specific antigens from bystander T cells. In FucoID, which is based on...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

AstraZeneca’s oncology R&D chief José Baselga sees the pharma’s push into ADCs as prologue for its quiet move into cell therapies, as the company builds up a stable of new modalities and targets...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more patients with treatment-naïve metastatic castration-resistant prostate cancer. While the small molecule inhibitor of AKT, AKT2...
...for HCQ” ). Targets AKT (AKT1; PKB; PKBA) - Protein kinase B AKT2 (PKBB) - Protein kinase B beta...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Dec 26, 2019
Company News

Dec. 27 Company Quick Takes: Immunomedics, Qiagen, Eisai-Gilead, Melinta, Denovo-Rumpus

FDA again reviewing Immunomedics’ ADC FDA has accepted a resubmitted BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of sacituzumab govitecan to treat third-line metastatic triple-negative breast cancer. The company had received a complete response...
BioCentury | Dec 9, 2019
Company News

With $2.7B ArQule buyout, Merck is latest pharma to jump into Btk race

With its proposed acquisition of ArQule, Merck will join the ranks of at least three other pharmas adding Btk inhibitors to their portfolios while appearing to pay much less than its peers. The $2.7 billion...
BioCentury | Aug 5, 2019
Clinical News

Bladder cancer data gives Tecentriq another first-line win

With more positive data in first-line bladder cancer, Roche's Tecentriq could become the leading immunotherapy agent for the indication. An interim analysis of the 1,213-patient Phase III IMvigor-130 trial showed Tecentriq atezolizumab plus chemotherapy met...
BioCentury | Jul 24, 2019
Translation in Brief

Unraveling checkpoint responses in PD-L1-negative cancers

A new study from City of Hope offers a long-sought explanation for why some patients lacking PD-L1 expression on their tumors respond to antibodies against the target, and uncovers a way to boost NK cell...
BioCentury | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

...1 Genetech Inc. / Roche (SIX:ROG; OTCQX:RHHBY) Ipatasertib Protein kinase B (AKT; AKT1; PKB; PKBA); AKT2...
BioCentury | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
Items per page:
1 - 10 of 671